DE69332758D1 - Taxol zur behandlung von lymphomen und brustkrebs und zur verminderung der multi-drug resistenz gegen taxol - Google Patents

Taxol zur behandlung von lymphomen und brustkrebs und zur verminderung der multi-drug resistenz gegen taxol

Info

Publication number
DE69332758D1
DE69332758D1 DE69332758T DE69332758T DE69332758D1 DE 69332758 D1 DE69332758 D1 DE 69332758D1 DE 69332758 T DE69332758 T DE 69332758T DE 69332758 T DE69332758 T DE 69332758T DE 69332758 D1 DE69332758 D1 DE 69332758D1
Authority
DE
Germany
Prior art keywords
taxol
breast cancer
drug resistance
patient
reducing multi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69332758T
Other languages
English (en)
Inventor
Wyndham H Wilson
Robert Wittes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Application granted granted Critical
Publication of DE69332758D1 publication Critical patent/DE69332758D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69332758T 1992-09-22 1993-09-22 Taxol zur behandlung von lymphomen und brustkrebs und zur verminderung der multi-drug resistenz gegen taxol Expired - Lifetime DE69332758D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95038092A 1992-09-22 1992-09-22
PCT/US1993/008983 WO1994006422A1 (en) 1992-09-22 1993-09-22 Use of taxol for treating lymphomas and breast cancer

Publications (1)

Publication Number Publication Date
DE69332758D1 true DE69332758D1 (de) 2003-04-17

Family

ID=25490363

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69332758T Expired - Lifetime DE69332758D1 (de) 1992-09-22 1993-09-22 Taxol zur behandlung von lymphomen und brustkrebs und zur verminderung der multi-drug resistenz gegen taxol

Country Status (8)

Country Link
US (2) US5496846A (de)
EP (1) EP0661969B1 (de)
JP (1) JP3020277B2 (de)
AT (1) ATE234088T1 (de)
AU (1) AU680441B2 (de)
CA (1) CA2145190A1 (de)
DE (1) DE69332758D1 (de)
WO (1) WO1994006422A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994341A (en) * 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
US7304204B2 (en) 1995-08-31 2007-12-04 Roslin Institute Ungulates produced by nuclear transfer of G1 cells
GB9517779D0 (en) 1995-08-31 1995-11-01 Roslin Inst Edinburgh Biological manipulation
GB2340493B (en) * 1995-08-31 2000-06-21 Roslin Inst Unactivated oocytes as cytoplast recipients for nuclear transfer
GB9517780D0 (en) 1995-08-31 1995-11-01 Roslin Inst Edinburgh Biological manipulation
DE69734060T2 (de) 1996-05-24 2006-06-29 Angiotech Pharmaceuticals, Inc., Vancouver Zubereitungen und verfahren zur behandlung oder prävention von krankheiten der körperpassagewege
AU3740997A (en) * 1996-08-26 1998-03-19 Bristol-Myers Squibb Company Sulfenamide taxane derivatives
US20030157187A1 (en) * 1996-12-02 2003-08-21 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating or preventing inflammatory diseases
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
US6495579B1 (en) 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
US7361804B1 (en) 1997-02-19 2008-04-22 Roslin Institute (Edinburgh) Unactivated oocytes in nuclear transfer to produce ungulates
JP3896435B2 (ja) * 1997-12-17 2007-03-22 アークレイ株式会社 センサおよびセンサ集合体
CA2326485C (en) * 1998-04-01 2008-12-09 Rtp Pharma Inc. Anticancer compositions
EP1171117A4 (de) * 1999-04-22 2002-08-07 American Bioscience Inc Langzeitverabreichung von pharmakologisch aktiven mitteln
EP1685835A3 (de) * 1999-04-22 2006-08-09 American Bioscience, Inc. Langzeitapplikation subtherapeutischer Mengen pharmakologischer Wirkstoffe
US6294546B1 (en) 1999-08-30 2001-09-25 The Broad Of Trustees Of The Leland Stanford Junior University Uses of diterpenoid triepoxides as an anti-proliferative agent
WO2001076559A1 (en) 2000-04-10 2001-10-18 Teva Pharmaceutical Industries Ltd. Method 0f administration of paclitaxel-plasma protein formulation
US6410059B1 (en) * 2000-10-20 2002-06-25 Council Of Scientific And Industrial Research Pharmaceutical composition containing cow urine distillate and an antibiotic
CZ294371B6 (cs) * 2002-06-10 2004-12-15 Pliva - Lachema, A. S. Stabilizovaná farmaceutická kompozice na bázi polyoxyethylovaného ricinového oleje a způsob její přípravy
MXPA06008408A (es) * 2004-01-27 2007-01-30 Univ South Florida Compuestos para union al factor de crecimiento unidos a un calixareno.
EP1720874A4 (de) * 2004-02-24 2010-03-03 Bioaxone Therapeutique Inc 4-substituierte piperidinderivate
US7989490B2 (en) * 2004-06-02 2011-08-02 Cordis Corporation Injectable formulations of taxanes for cad treatment
US7459562B2 (en) * 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
US20060252823A1 (en) * 2005-05-04 2006-11-09 Deck Lorraine M Isocoumarin-based inhibitors of urokinase-type plasminogen activator
US9517240B2 (en) 2006-09-26 2016-12-13 The Regents Of The University Of California Methods and compositions for cancer prevention and treatment
WO2008039482A2 (en) * 2006-09-26 2008-04-03 The Regents Of The University Of California Methods and compositions for cancer prevention and treatment
US20080227853A1 (en) * 2007-03-13 2008-09-18 Bionature E. A. Limited Androgene membrane receptor agonist
US8403291B2 (en) * 2007-06-21 2013-03-26 Michael Wallace Howlett Tube slide clamp with extending finger grips
FR2933405B1 (fr) * 2008-07-03 2010-08-13 Centre Nat Rech Scient Derives ferroceniques a activite anticancereuse
US10149856B2 (en) 2015-01-26 2018-12-11 BioAxone BioSciences, Inc. Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors
US10857157B2 (en) 2015-01-26 2020-12-08 BioAxone BioSciences, Inc. Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors
US10106525B2 (en) 2015-01-26 2018-10-23 BioAxone BioSciences, Inc. Rho kinase inhibitor BA-1049 (R) and active metabolites thereof
US11198680B2 (en) 2016-12-21 2021-12-14 BioAxone BioSciences, Inc. Rho kinase inhibitor BA-1049 (R) and active metabolites thereof
US10537567B2 (en) 2017-07-11 2020-01-21 BioAxone BioSciences, Inc. Kinase inhibitors for treatment of disease

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6630454B2 (en) * 2001-09-10 2003-10-07 Ramot At Tel-Aviv University Ltd. Method and pharmaceutical composition for the treatment of cancer

Also Published As

Publication number Publication date
WO1994006422A1 (en) 1994-03-31
JPH08501560A (ja) 1996-02-20
AU5135793A (en) 1994-04-12
JP3020277B2 (ja) 2000-03-15
ATE234088T1 (de) 2003-03-15
EP0661969B1 (de) 2003-03-12
AU680441B2 (en) 1997-07-31
USRE40839E1 (en) 2009-07-07
CA2145190A1 (en) 1994-03-31
US5496846A (en) 1996-03-05
EP0661969A1 (de) 1995-07-12

Similar Documents

Publication Publication Date Title
DE69332758D1 (de) Taxol zur behandlung von lymphomen und brustkrebs und zur verminderung der multi-drug resistenz gegen taxol
DE3684190D1 (de) Verwendung von tetrahydrobiopterinen zur herstellung eines medikaments zur behandlung von kinderautismus.
DE69213814D1 (de) Melatoninderivate zur Behandlung von Schlafstörungen und zur Pre-Anästhesie
KR900015730A (ko) 정신장해 치료방해
DE10199020I2 (de) Galanthamin oder dessen Analoge zur Behandlung derAlzheimerschen Krankheit.
ATE144420T1 (de) Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen
DK0668763T3 (da) Anvendelse af phenserin til fremstillingen af lægemidler til behandlingen af kognitive sygdomme
DE69012261T2 (de) Verwendung von Sertralin zur Behandlung verfrühter Ejakulation.
ATE137965T1 (de) Verwendung von tomoxetine zur behandlung von funktionsstörungen der niedrigen harnwege
DE69825279D1 (de) Verwendung von glukosamin und glukosaminderivaten zur schnellen linderung von juckreiz oder lokalisiertem schmerz
DE59605959D1 (de) Verwendung von Immunglobulin-Präparationen zur Herstellung eines Medikaments zur oralen Verabreichung zur Behandlung und Prophylaxe chronischer Schmerzzustände
KR890003390A (ko) 골다공증 및 관련된 장해의 치료방법
MXPA00010254A (es) Tratamiento de disfuncion sexual en ciertos grupos de pacientes.
DE69924483D1 (de) Kombinationstherapie zur behandlung von tumoren
ATE141796T1 (de) 2',5'-oligoadenylat-derivate zur verwendung als heilmittel
KR890000108A (ko) 종양 치료용 약제학적 조성물
ATE70181T1 (de) Verwendung von oxochinazolinderivaten bei der behandlung von hyperurikaemie.
HUP9903679A2 (hu) Olanzapin alkalmazása bipoláris zavar kezelésére szolgáló gyógyszerkészítmények előállítására
DE69010523D1 (de) Kit oder Zusammensetzung zur Vorbeugung oder Behandlung von HIV-1 Infektionen.
ATE195876T1 (de) Reinigung einer den müller-mischtumor inhibierenden substanz und behandlung von einigen tumoren
KR900017599A (ko) 종양 치료용 약학 조성물
DE68909750D1 (de) Vorrichtung zur therapeutischen behandlung von lumbago sowie lumbago/ischias.
TR199901385T2 (xx) Piperidin t�revleri.
BR9914570A (pt) Processo para o tratamento da esquizofrenia bem como agentes para o emprego neste processo
ATE295731T1 (de) Olanzapine zur behandlung von drogenmissbrauch

Legal Events

Date Code Title Description
8332 No legal effect for de